Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?

Immunotherapy

Volumn 6, Issue 4, 2014, Pages 371-375

  Brown, Michael P ^a,b   Staudacher, Alexander H ^b,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

antibody drug conjugate; bystander effect; cathepsin

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BYSTANDER EFFECT; CANCER CELL; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG MECHANISM; HODGKIN DISEASE; HUMAN; LONG TERM SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE;

EID: 84900386492     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.13     Document Type: Article

References (25)

1. Drachman JG, Senter PD. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. Hematology. Am. Soc. Hematol. Educ. Program 2013, 306-310 (2013).
2. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin. Cancer Res. 19(1), 22-27 (2013).
3. Oflazoglu E, Stone IJ, Gordon KA et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110(13), 4370-4372 (2007). (Pubitemid 351377803)
4. Crocker J, Burnett D, Jones EL. Immunohistochemical demonstration of cathepsin B in the macrophages of benign and malignant lymphoid tissues. J. Pathol. 142(1), 87-94 (1984). (Pubitemid 14194747)
5. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30(7), 631-637 (2012).
6. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk. Lymphoma 8(4-5), 283-313 (1992). (Pubitemid 23035516)
7. Kuppers R. The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 9(1), 15-27 (2009).
8. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 17(20), 6428-6436 (2011).
9. Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br. J. Haematol. 152(2), 182-190 (2011).
10. Diefenbach CSM, Leonard JP. Targeting CD30 in Hodgkin lymphoma: antibody-drug conjugates make a difference. Hematology. Am. Soc. Hematol. Educ. Program 2012, 162-166 (2012).
11. Sutherland MS, Sanderson RJ, Gordon KA et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281(15), 10540-10547 (2006). (Pubitemid 43864594)
12. Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16(3), 888-897 (2010).
13. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol. 142(1), 69-73 (2008). (Pubitemid 351783148)
14. Advani R, Oki Y, Shustov AR, Grove LE, Bartlett N. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a Phase II study. J. Clin. Oncol. 30(15 Suppl.), Abstract 8070 (2012).
15. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362(10), 875-885 (2010).
16. Ma Y, Visser L, Roelofsen H et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 111(4), 2339-2346 (2008). (Pubitemid 351451442)
17. Polson AG, Calemine-Fenaux J, Chan P et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69(6), 2358-2364 (2009).
18. DiJoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21(11), 2240-2245 (2007). (Pubitemid 350011695)
19. Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin. Lymphoma Myeloma Leuk. 12(4), 280-283 (2012).
20. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1(1), 54-67 (2011).
21. Ma Y, Adjemian S, Mattarollo SR et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38(4), 729-741 (2013).
22. Shree T, Olson OC, Elie BT et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25(23), 2465-2479 (2011).
23. Kumpel BM, De HM, Koene HR, van de Winkel JG, Goodrick MJ. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16). Clin. Exp. Immunol. 132(1), 81-86 (2003). (Pubitemid 36418909)
24. Hulkower KI, Butler CC, Linebaugh BE et al. Fluorescent microplate assay for cancer cell-associated cathepsin B. Eur. J. Biochem. 267(13), 4165-4170 (2000). (Pubitemid 30436112)
25. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196(4), 493-503 (2002).